Press Releases

We lead the synthetic biology industry, having developed and successfully commercialized the most Lab-to-Market™ ingredients. Our sustainable ingredients are used in thousands of top global brands, including our own family of consumer brands in Clean Beauty and Health markets.

AMYRIS TO PRESENT AT THE 42nd ANNUAL COWEN HEALTH CARE CONFERENCE

EMERYVILLE, Calif., Feb. 28, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform today announced that management will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 1:30 pm ET.

A live webcast of the presentation and a replay will be available on the Investor Relations section of the company's website at https://investors.amyris.com/events-and-presentations.

About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ technology platform. This Amyris technology platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com.

Amyris, the Amyris logo and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

 

SOURCE Amyris, Inc.

For further information: Argot Partners Jason Finkelstein, amyris@argotpartners.com, +1 (212) 600-1902; Amyris, Inc., Paul Vincent, vincent@amyris.com, +1 (510) 450-0761: Amyris, Inc., Beth Bannerman, bannerman@amyris.com, +1 (510) 914-0022
Contact Us

For media inquiries, please contact: info@amyris.com
For investor inquiries, please contact: investor@amyris.com